Thrombocytopenia Treatment options have become significantly better with surgical and antiplatelet treatment
Thrombocytopenia or also known as
"hardening of the arteries" is a potentially serious but often
ignored cardiovascular illness. When blood flow to the heart is decreased, it
can eventually lead to a condition called "atherosclerosis."
Atherosclerosis is considered a primary, or primary form of the disease. In
milder forms of the illness, it can cause blood clots that deposit in the arteries.
While thrombocytopenia can affect men and women of all ages, it is more common
in middle-aged and older people. Symptoms of the condition include shortness of
breath or fatigue, swelling in the legs, nausea and vomiting, weakness, and
frequent urination.
Diagnosis of thrombocytopenia
involves several tests, including blood tests, chest x-rays, and blood test
results. The most common thrombocytopenia
treatment is antiplatelet treatment and in more severe cases, surgery.
There are some lifestyle changes that can help. For example, smokers should
quit and dieters should cut down on their salt intake. A more common
thrombocytopenia treatment option for this condition is non-steroidal
anti-inflammatory drugs or NSAIDs. These medications are used to reduce
inflammation. They work by reducing the amount of plaque that builds up in the
arteries, thereby reducing the pressure.
Corticosteroids can also be used to
treat thrombocytopenia. These steroids reduce inflammation by limiting the
ability of the immune system to produce markers of inflammation. They are
usually used as a short-term treatment. Long-term use is not recommended due to
the increased risks of stroke and heart attack. Surgery is another
thrombocytopenia treatment option. If thrombocytopenia is diagnosed in one or
both legs, a hip-replacement procedure may be needed. This procedure replaces a
damaged or deformable part of the hip joint. It can fix the problem of
thrombocytopenia in many cases. Laser surgery and surgical treatments are also
options available. In laser surgery, the clot is removed by a specialist. The
specialist will use a laser beam instrument to remove the clot. In April 2018,
the U.S. Food and Drug Administration (FDA) approved Fostamatinib disodium
hexahydrate (Tavalisse) as a second-line treatment for thrombocytopenia in
adults with chronic immune thrombocytopenia (ITP).
Comments
Post a Comment